Acute Myeloid Leukemia Clinical Trial
Official title:
A Phase 1, Open Label, Dose Escalation, and Dose Expansion Study to Assess the Safety, Tolerability, and Preliminary Antileukemic Activity of GDX012 in Patients With Minimal Residual Disease (MRD) Positive Acute Myeloid Leukemia
Verified date | July 2022 |
Source | GammaDelta Therapeutics Limited |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this first-in-human study is to assess the safety, tolerability, antileukemic activity and maximum tolerated dose (MTD) of GDX012 in AML patients who are MRD positive by multiparametric flow cytometry. The study will consist of a dose escalation stage to evaluate various doses of GDX012 after a lymphodepletion regimen comprising fludarabine and cyclophosphamide. Following determination of the MTD of GDX012, the study will expand at the MTD. Patients will be followed up for 12 months, after receiving GDX012.
Status | Terminated |
Enrollment | 3 |
Est. completion date | June 3, 2022 |
Est. primary completion date | June 3, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - = 18 years old - Weight = 40 kg - Anticipated life expectancy > 3 months prior to lymphodepletion - Karnofsky Performance Score = 70% - Histologically confirmed diagnosis of AML - In complete response (CR) (including CRi/CRp); patients in first, second or subsequent CR (including CRi/CRp) are permitted - MRD detected in bone marrow by MFC - Negative pregnancy test (females of childbearing potential only) - Agree to use effective birth control - Left ventricular ejection fraction (LVEF) = 50% - Platelet Count = 20 x 109/L - Prothrombin Time or INR = 1.5 x ULN (unless receiving therapeutic anticoagulation) - Partial Thromboplastin Time = 1.5 x ULN (unless receiving therapeutic anticoagulation) - Hemoglobin = 8.0 g/dL - Creatinine Clearance = 40mL/min - Serum Total Bilirubin = 1.5 x ULN (unless documented Gilbert's Syndrome with Direct Bilirubin < 35% of Total Bilirubin) - ALT = 2.5 x ULN Exclusion Criteria: - Cytotoxic chemotherapy within 3 weeks - Immune therapy within 4 weeks - Immunosuppressive therapy within 2 weeks (with exceptions) - Investigational treatment or interventional clinical trial within 4 weeks or 5 half-lives (if known), whichever is longer - Major surgery within 4 weeks and/or not fully recovered from surgery-related toxicities - Known hypersensitivity to chemotherapy, other agents, or excipients used in this study - Female patient that is pregnant or lactating/breastfeeding - Ongoing toxicity from prior anti-cancer therapy that have not recovered to = Grade 1 (with exceptions) - History of chronic or recurrent autoimmune or immune-mediated disease requiring steroids or other immunosuppressive treatments (including anti-tumor necrosis factor agents) - Active CNS involvement (i.e. leukemic infiltration) - Any other malignancy that requires active therapy - Uncontrolled intercurrent illness (i.e. acute coronary syndrome in the last 6 months) - Active infection with HIV, Hepatitis B or Hepatitis C NOTE: other protocol defined inclusion/exclusion criteria may apply. |
Country | Name | City | State |
---|---|---|---|
United States | City of Hope | Duarte | California |
Lead Sponsor | Collaborator |
---|---|
GammaDelta Therapeutics Limited |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Incidence of treatment emergent adverse events (AEs) and serious adverse events (SAEs) | AEs and SAEs occurring following administration of GDX012 | Up to 100 days | |
Primary | Incidence of treatment emergent clinically significant abnormal laboratory assessments | Standard clinical laboratory assessments for organ function (i.e. heart, kidney, liver) | Up to 100 days | |
Primary | Incidence of dose limiting toxicities (DLTs) | DLTs occurring following administration of GDX012, measured using CTCAE 5.0 criteria | Up to 100 days | |
Primary | Establish the maximum tolerated dose (MTD) of GDX012 | Up to 100 days | ||
Secondary | Evaluate the antileukemic activity of GDX012 | Minimal residual disease (MRD) assessed by flow cytometry | Up to 1 year | |
Secondary | Evaluate the antileukemic activity of GDX012 | Incidence of patients converting from MRD positive to MRD negative | Up to 1 year | |
Secondary | Evaluate the antileukemic activity of GDX012 | Progression-free survival (PFS) and overall survival (OS) | Up to 1 year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05400122 -
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
|
Phase 1 | |
Recruiting |
NCT04460235 -
Immunogenicity of an Anti-pneumococcal Combined Vaccination in Acute Leukemia or Lymphoma
|
Phase 4 | |
Completed |
NCT03678493 -
A Study of FMT in Patients With AML Allo HSCT in Recipients
|
Phase 2 | |
Completed |
NCT04022785 -
PLX51107 and Azacitidine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
|
Phase 1 | |
Recruiting |
NCT05424562 -
A Study to Assess Change in Disease State in Adult Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy Receiving Oral Venetoclax Tablets in Canada
|
||
Completed |
NCT03197714 -
Clinical Trial of OPB-111077 in Patients With Relapsed or Refractory Acute Myeloid Leukaemia
|
Phase 1 | |
Terminated |
NCT03224819 -
Study of Emerfetamab (AMG 673) in Adults With Relapsed/Refractory Acute Myeloid Leukemia (AML)
|
Early Phase 1 | |
Active, not recruiting |
NCT04070768 -
Study of the Safety and Efficacy of Gemtuzumab Ozogamicin (GO) and Venetoclax in Patients With Relapsed or Refractory CD33+ Acute Myeloid Leukemia:Big Ten Cancer Research Consortium BTCRC-AML17-113
|
Phase 1 | |
Active, not recruiting |
NCT03844048 -
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
|
Phase 3 | |
Active, not recruiting |
NCT04107727 -
Trial to Compare Efficacy and Safety of Chemotherapy/Quizartinib vs Chemotherapy/Placebo in Adults FMS-like Tyrosine Kinase 3 (FLT3) Wild-type Acute Myeloid Leukemia (AML)
|
Phase 2 | |
Recruiting |
NCT04920500 -
Bioequivalence of Daunorubicin Cytarabine Liposomes in Naive AML Patients
|
N/A | |
Recruiting |
NCT04385290 -
Combination of Midostaurin and Gemtuzumab Ozogamicin in First-line Standard Therapy for Acute Myeloid Leukemia (MOSAIC)
|
Phase 1/Phase 2 | |
Recruiting |
NCT03897127 -
Study of Standard Intensive Chemotherapy Versus Intensive Chemotherapy With CPX-351 in Adult Patients With Newly Diagnosed AML and Intermediate- or Adverse Genetics
|
Phase 3 | |
Active, not recruiting |
NCT04021368 -
RVU120 in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome
|
Phase 1 | |
Recruiting |
NCT03665480 -
The Effect of G-CSF on MRD After Induction Therapy in Newly Diagnosed AML
|
Phase 2/Phase 3 | |
Completed |
NCT02485535 -
Selinexor in Treating Patients With Intermediate- and High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome After Transplant
|
Phase 1 | |
Enrolling by invitation |
NCT04093570 -
A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose), With a Food Effect Substudy at Select Study Centers
|
Phase 2 | |
Recruiting |
NCT04069208 -
IA14 Induction in Young Acute Myeloid Leukemia
|
Phase 2 | |
Recruiting |
NCT05744739 -
Tomivosertib in Relapsed or Refractory Acute Myeloid Leukemia (AML)
|
Phase 1 | |
Recruiting |
NCT04969601 -
Anti-Covid-19 Vaccine in Children With Acute Leukemia and Their Siblings
|
Phase 1/Phase 2 |